JP2021527044A - 統合的ストレス応答経路の阻害剤 - Google Patents
統合的ストレス応答経路の阻害剤 Download PDFInfo
- Publication number
- JP2021527044A JP2021527044A JP2020567794A JP2020567794A JP2021527044A JP 2021527044 A JP2021527044 A JP 2021527044A JP 2020567794 A JP2020567794 A JP 2020567794A JP 2020567794 A JP2020567794 A JP 2020567794A JP 2021527044 A JP2021527044 A JP 2021527044A
- Authority
- JP
- Japan
- Prior art keywords
- formula
- alkyl
- haloalkyl
- compound
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 ***=CC=C1[Np]C(*)(N)NC1=** Chemical compound ***=CC=C1[Np]C(*)(N)NC1=** 0.000 description 27
- DTQVDTLACAAQTR-UHFFFAOYSA-N OC(C(F)(F)F)=O Chemical compound OC(C(F)(F)F)=O DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- FRSQWGPTUUPBPJ-UHFFFAOYSA-N CC(C)(C)OC(NC(CC1)CCN1N)=O Chemical compound CC(C)(C)OC(NC(CC1)CCN1N)=O FRSQWGPTUUPBPJ-UHFFFAOYSA-N 0.000 description 2
- GYOFXQNABVOHIB-UHFFFAOYSA-N FC(c(cc1)ccc1OCC1OC1)(F)F Chemical compound FC(c(cc1)ccc1OCC1OC1)(F)F GYOFXQNABVOHIB-UHFFFAOYSA-N 0.000 description 2
- NOGJAAYHMGDTSD-UHFFFAOYSA-N C(CNN(CC1)CCN1NCCc1ccccc1)c1ccccc1 Chemical compound C(CNN(CC1)CCN1NCCc1ccccc1)c1ccccc1 NOGJAAYHMGDTSD-UHFFFAOYSA-N 0.000 description 1
- GXPUQTKHWNOJSN-UHFFFAOYSA-N C1c(ccnc2)c2OC1 Chemical compound C1c(ccnc2)c2OC1 GXPUQTKHWNOJSN-UHFFFAOYSA-N 0.000 description 1
- CEDHFNZEZCCEMX-UHFFFAOYSA-N CC1Oc(ccc(Cl)c2)c2NC1 Chemical compound CC1Oc(ccc(Cl)c2)c2NC1 CEDHFNZEZCCEMX-UHFFFAOYSA-N 0.000 description 1
- IQGFCZNNUOMZSJ-UHFFFAOYSA-N CNN(CC1)CCN1NC Chemical compound CNN(CC1)CCN1NC IQGFCZNNUOMZSJ-UHFFFAOYSA-N 0.000 description 1
- LNQOUTFXGBPXJO-UHFFFAOYSA-N COC(CN=C)CO Chemical compound COC(CN=C)CO LNQOUTFXGBPXJO-UHFFFAOYSA-N 0.000 description 1
- JOQKDQCNYBRFBJ-UHFFFAOYSA-N COc(cc1)cc2c1[o]c(C(NN(CC1)CCC1N)=O)c2 Chemical compound COc(cc1)cc2c1[o]c(C(NN(CC1)CCC1N)=O)c2 JOQKDQCNYBRFBJ-UHFFFAOYSA-N 0.000 description 1
- XCBJQPQEUHRVAW-UHFFFAOYSA-N COc(cc1)cc2c1[o]c(N)c2 Chemical compound COc(cc1)cc2c1[o]c(N)c2 XCBJQPQEUHRVAW-UHFFFAOYSA-N 0.000 description 1
- AMXDZEBUGTWEKT-UHFFFAOYSA-N COc(cc1)cc2c1[o]c(S)c2 Chemical compound COc(cc1)cc2c1[o]c(S)c2 AMXDZEBUGTWEKT-UHFFFAOYSA-N 0.000 description 1
- JJXPTUWJVQUHKN-UHFFFAOYSA-N COc(cc1)cc2c1[o]cc2 Chemical compound COc(cc1)cc2c1[o]cc2 JJXPTUWJVQUHKN-UHFFFAOYSA-N 0.000 description 1
- NZFWVTJSDQXUCD-UHFFFAOYSA-N COc1ccc2[o]c(C(NN(CC3)CCC3NOC(C(F)(F)F)=O)=O)cc2c1 Chemical compound COc1ccc2[o]c(C(NN(CC3)CCC3NOC(C(F)(F)F)=O)=O)cc2c1 NZFWVTJSDQXUCD-UHFFFAOYSA-N 0.000 description 1
- CEDHFNZEZCCEMX-ZCFIWIBFSA-N C[C@H]1Oc(ccc(Cl)c2)c2NC1 Chemical compound C[C@H]1Oc(ccc(Cl)c2)c2NC1 CEDHFNZEZCCEMX-ZCFIWIBFSA-N 0.000 description 1
- FFXYELKMBQVESY-UHFFFAOYSA-N C[IH]c1ccc(cc(cc2)Cl)c2n1 Chemical compound C[IH]c1ccc(cc(cc2)Cl)c2n1 FFXYELKMBQVESY-UHFFFAOYSA-N 0.000 description 1
- PXNNCGPMQDJPPY-UHFFFAOYSA-N C[O](C(CN=C)CO)=C Chemical compound C[O](C(CN=C)CO)=C PXNNCGPMQDJPPY-UHFFFAOYSA-N 0.000 description 1
- NWESJZZPAJGHRZ-UHFFFAOYSA-N Cc(cc1)cc([N+]([O-])=O)c1Cl Chemical compound Cc(cc1)cc([N+]([O-])=O)c1Cl NWESJZZPAJGHRZ-UHFFFAOYSA-N 0.000 description 1
- LETXOKWPIXJCJA-UHFFFAOYSA-N Cc(cc1)cc(cc2)c1nc2C(NN(CCNC1)C1[F]C(C(O)=O)(F)F)=O Chemical compound Cc(cc1)cc(cc2)c1nc2C(NN(CCNC1)C1[F]C(C(O)=O)(F)F)=O LETXOKWPIXJCJA-UHFFFAOYSA-N 0.000 description 1
- REDGLYJNYHJYJW-UHFFFAOYSA-N Cc(cc1NC2)ccc1OC2C(NN1CCNCC1)=O Chemical compound Cc(cc1NC2)ccc1OC2C(NN1CCNCC1)=O REDGLYJNYHJYJW-UHFFFAOYSA-N 0.000 description 1
- JUJMBVIXAJWFLD-UHFFFAOYSA-N Cc1cc2ccc(C(NN3CCN(CC(COc4ccc(C(F)(F)F)cc4)O)CC3)=O)nc2cc1 Chemical compound Cc1cc2ccc(C(NN3CCN(CC(COc4ccc(C(F)(F)F)cc4)O)CC3)=O)nc2cc1 JUJMBVIXAJWFLD-UHFFFAOYSA-N 0.000 description 1
- XCALAYIRFYALSX-UHFFFAOYSA-N Cc1nc(cc(cc2)Cl)c2[s]1 Chemical compound Cc1nc(cc(cc2)Cl)c2[s]1 XCALAYIRFYALSX-UHFFFAOYSA-N 0.000 description 1
- GZBZALMXJLNTMS-UHFFFAOYSA-N Clc(cc1)cc(C2)c1OC2I Chemical compound Clc(cc1)cc(C2)c1OC2I GZBZALMXJLNTMS-UHFFFAOYSA-N 0.000 description 1
- SRXDDFVRGSCDSL-UHFFFAOYSA-N Clc(cc1)cc(NC2)c1OC2I Chemical compound Clc(cc1)cc(NC2)c1OC2I SRXDDFVRGSCDSL-UHFFFAOYSA-N 0.000 description 1
- JXQCQVXVYLKKEV-UHFFFAOYSA-N Clc(cc1)cc(cc2)c1nc2I Chemical compound Clc(cc1)cc(cc2)c1nc2I JXQCQVXVYLKKEV-UHFFFAOYSA-N 0.000 description 1
- CPJOPFBXUHIQQL-UHFFFAOYSA-N Clc(cc1)cc2c1[o]cc2 Chemical compound Clc(cc1)cc2c1[o]cc2 CPJOPFBXUHIQQL-UHFFFAOYSA-N 0.000 description 1
- CXWLXKZIXLOBCC-UHFFFAOYSA-N Clc(cc1)cnc1I Chemical compound Clc(cc1)cnc1I CXWLXKZIXLOBCC-UHFFFAOYSA-N 0.000 description 1
- WMVHXRNLZBQWFK-UHFFFAOYSA-N Clc1ccc2OCCNc2c1 Chemical compound Clc1ccc2OCCNc2c1 WMVHXRNLZBQWFK-UHFFFAOYSA-N 0.000 description 1
- PWRBCZZQRRPXAB-UHFFFAOYSA-N Clc1cnccc1 Chemical compound Clc1cnccc1 PWRBCZZQRRPXAB-UHFFFAOYSA-N 0.000 description 1
- GQHWSLKNULCZGI-UHFFFAOYSA-N FC(Oc1ccccc1)(F)F Chemical compound FC(Oc1ccccc1)(F)F GQHWSLKNULCZGI-UHFFFAOYSA-N 0.000 description 1
- SKGRFPGOGCHDPC-UHFFFAOYSA-N FC(c(cc1)ccc1I)(F)F Chemical compound FC(c(cc1)ccc1I)(F)F SKGRFPGOGCHDPC-UHFFFAOYSA-N 0.000 description 1
- UMWOUFHXYAAMSW-UHFFFAOYSA-N Fc(cc(cc1)OCC2OC2)c1Cl Chemical compound Fc(cc(cc1)OCC2OC2)c1Cl UMWOUFHXYAAMSW-UHFFFAOYSA-N 0.000 description 1
- DZCIURLVVVMUFK-UHFFFAOYSA-N Fc(cc(cc1)OCCCBr)c1Cl Chemical compound Fc(cc(cc1)OCCCBr)c1Cl DZCIURLVVVMUFK-UHFFFAOYSA-N 0.000 description 1
- WSEYUIYEJLBFFA-UHFFFAOYSA-N IC(C1)Oc2c1ccnc2 Chemical compound IC(C1)Oc2c1ccnc2 WSEYUIYEJLBFFA-UHFFFAOYSA-N 0.000 description 1
- UYJCIKQYHGTLML-UHFFFAOYSA-N NC(C1)Oc(cc2)c1cc2N Chemical compound NC(C1)Oc(cc2)c1cc2N UYJCIKQYHGTLML-UHFFFAOYSA-N 0.000 description 1
- UMTUWJPIMLZJPE-UHFFFAOYSA-N NC(CC1)CCN1NC(c1ccc(cc(cc2)Cl)c2n1)=O Chemical compound NC(CC1)CCN1NC(c1ccc(cc(cc2)Cl)c2n1)=O UMTUWJPIMLZJPE-UHFFFAOYSA-N 0.000 description 1
- IZKQPHPSANYONZ-UHFFFAOYSA-N Nc(cc1)cc(cc2)c1cc2I Chemical compound Nc(cc1)cc(cc2)c1cc2I IZKQPHPSANYONZ-UHFFFAOYSA-N 0.000 description 1
- GOGZBMRXLADNEV-UHFFFAOYSA-N Nc(cc1)cc(cc2)c1cc2N Chemical compound Nc(cc1)cc(cc2)c1cc2N GOGZBMRXLADNEV-UHFFFAOYSA-N 0.000 description 1
- GMOLCSICTCPZCU-UHFFFAOYSA-N Nc(cc1)cc2c1[o]cc2 Chemical compound Nc(cc1)cc2c1[o]cc2 GMOLCSICTCPZCU-UHFFFAOYSA-N 0.000 description 1
- YJMADHMYUJFMQE-UHFFFAOYSA-N Nc1ccc2OCCc2c1 Chemical compound Nc1ccc2OCCc2c1 YJMADHMYUJFMQE-UHFFFAOYSA-N 0.000 description 1
- IMXSJPPTIYFNMX-UHFFFAOYSA-N O=C(C(CNc1c2)Oc1ccc2Cl)NN1CCN(CCCOc(cc2F)ccc2Cl)CC1 Chemical compound O=C(C(CNc1c2)Oc1ccc2Cl)NN1CCN(CCCOc(cc2F)ccc2Cl)CC1 IMXSJPPTIYFNMX-UHFFFAOYSA-N 0.000 description 1
- CPMQSGRCSYNQNJ-UHFFFAOYSA-N OC(CNC(CC1)CCN1NC(c1ccc(cc(cc2)Cl)c2n1)=O)COc(cc1F)ccc1Cl Chemical compound OC(CNC(CC1)CCN1NC(c1ccc(cc(cc2)Cl)c2n1)=O)COc(cc1F)ccc1Cl CPMQSGRCSYNQNJ-UHFFFAOYSA-N 0.000 description 1
- BAYGVMXZJBFEMB-UHFFFAOYSA-N Oc1ccc(C(F)(F)F)cc1 Chemical compound Oc1ccc(C(F)(F)F)cc1 BAYGVMXZJBFEMB-UHFFFAOYSA-N 0.000 description 1
- NKYDKCVZNMNZCM-UHFFFAOYSA-N Sc1nc(cc(cc2)Cl)c2[s]1 Chemical compound Sc1nc(cc(cc2)Cl)c2[s]1 NKYDKCVZNMNZCM-UHFFFAOYSA-N 0.000 description 1
- ZGRSYDOPCWIUOK-UHFFFAOYSA-N [NH-]c1ccc2[o]c(N)cc2c1 Chemical compound [NH-]c1ccc2[o]c(N)cc2c1 ZGRSYDOPCWIUOK-UHFFFAOYSA-N 0.000 description 1
- BFCFYVKQTRLZHA-UHFFFAOYSA-N [O-][N+](c1ccccc1Cl)=O Chemical compound [O-][N+](c1ccccc1Cl)=O BFCFYVKQTRLZHA-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
- C07D213/85—Nitriles in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/28—Nitrogen atoms
- C07D295/32—Nitrogen atoms acylated with carboxylic or carbonic acids, or their nitrogen or sulfur analogues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Gynecology & Obstetrics (AREA)
- Developmental Biology & Embryology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862681071P | 2018-06-05 | 2018-06-05 | |
| US62/681,071 | 2018-06-05 | ||
| PCT/US2019/035593 WO2019236710A1 (en) | 2018-06-05 | 2019-06-05 | Inhibitors of integrated stress response pathway |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021527044A true JP2021527044A (ja) | 2021-10-11 |
| JP2021527044A5 JP2021527044A5 (cg-RX-API-DMAC10.html) | 2022-06-13 |
Family
ID=68769460
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020567794A Pending JP2021527044A (ja) | 2018-06-05 | 2019-06-05 | 統合的ストレス応答経路の阻害剤 |
Country Status (13)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021508336A (ja) | 2017-12-13 | 2021-03-04 | プラクシス バイオテック エルエルシー | 統合的ストレス応答経路の阻害剤 |
| US12157746B2 (en) | 2018-06-05 | 2024-12-03 | Hoffmann-La Roche Inc. | Tetrahydro-1H-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease |
| JP2022536663A (ja) | 2019-06-12 | 2022-08-18 | プラクシス バイオテック エルエルシー | 統合的ストレス応答経路のモジュレーター |
| KR20220151635A (ko) | 2020-03-11 | 2022-11-15 | 에보텍 인터내셔널 게엠베하 | 통합 스트레스 반응 경로의 조절제 |
| CA3195290A1 (en) | 2020-10-22 | 2022-04-28 | Holly Victoria Atton | Modulators of the integrated stress response pathway |
| MX2023004677A (es) | 2020-10-22 | 2023-05-24 | Evotec Int Gmbh | Moduladores de la via de respuesta integrada al estres. |
| ES2997335T3 (en) | 2020-10-22 | 2025-02-17 | Evotec Int Gmbh | Modulators of the integrated stress response pathway |
| EP4001917A1 (en) | 2020-11-12 | 2022-05-25 | Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts | Inhibitors for use in treating liver disorders |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991001979A1 (fr) * | 1989-08-02 | 1991-02-21 | Fujisawa Pharmaceutical Co., Ltd. | Nouveaux derives d'aminopiperazine |
| JP2001511766A (ja) * | 1997-02-17 | 2001-08-14 | 藤沢薬品工業株式会社 | 新規アミノピペラジン誘導体 |
| JP2010533685A (ja) * | 2007-07-16 | 2010-10-28 | サノフイ−アベンテイス | ピラゾール3,5カルボキシレート誘導体、これらの調製および治療上の適用 |
| JP2016517442A (ja) * | 2013-03-15 | 2016-06-16 | ウォルター,ピーター | eIF2α経路の調節因子 |
| WO2017212425A1 (en) * | 2016-06-08 | 2017-12-14 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds as atf4 pathway inhibitors |
| WO2017212423A1 (en) * | 2016-06-08 | 2017-12-14 | Glaxosmithkline Intellectual Property Development Limited | Chemcical compounds |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5250528A (en) * | 1989-08-02 | 1993-10-05 | Fujisawa Pharmaceutical Co., Ltd. | New aminopiperazine derivatives |
| GB2236751B (en) | 1989-10-14 | 1993-04-28 | Wyeth John & Brother Ltd | Heterocyclic compounds |
| ID24525A (id) * | 1997-07-31 | 2000-07-20 | Hoffmann La Roche | Turunan-turunan hidroksikumaranon tersubstitusi-0 sebagai zat anti tumor dan zat antimetastatik |
| US20040133286A1 (en) | 2001-01-10 | 2004-07-08 | Takehiko Futatsugi | Automatic control system |
| US20050197350A1 (en) | 2003-03-31 | 2005-09-08 | Taisho Pharmaceutical Co., Ltd. | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof |
| CA2881078C (en) | 2004-06-24 | 2018-10-02 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
| JP4868731B2 (ja) | 2004-11-17 | 2012-02-01 | 独立行政法人理化学研究所 | 哺乳動物培養細胞由来の無細胞タンパク質合成システム |
| WO2009151800A1 (en) | 2008-05-07 | 2009-12-17 | Merck & Co., Inc. | Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment |
| US8273900B2 (en) | 2008-08-07 | 2012-09-25 | Novartis Ag | Organic compounds |
| EP2531490B1 (en) | 2010-02-02 | 2014-10-15 | Novartis AG | Cyclohexyl amide derivatives as crf receptor antagonists |
| WO2014072061A1 (en) | 2012-11-09 | 2014-05-15 | Biontech Ag | Method for cellular rna expression |
| TW201808888A (zh) | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| TWI920577B (zh) | 2016-05-05 | 2026-04-01 | 美商嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| TW201808903A (zh) | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| TW201808914A (zh) | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| CN110730777A (zh) | 2017-06-07 | 2020-01-24 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为atf4通路抑制剂的化学化合物 |
| EP3649108A1 (en) | 2017-07-03 | 2020-05-13 | GlaxoSmithKline Intellectual Property Development Limited | 2-(4-chlorophenoxy)-n-((1 -(2-(4-chlorophenoxy)ethynazetidin-3-yl)methyl)acetamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases |
| WO2019008506A1 (en) | 2017-07-03 | 2019-01-10 | Glaxosmithkline Intellectual Property Development Limited | N- (3- (2- (4-CHLOROPHENOXY) ACETAMIDO) BICYCLO [1.1.1] PENTAN-1-YL) -2-CYCLOBUTANE-1-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ATF4 INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER DISEASES |
| IL301709B2 (en) | 2017-08-09 | 2025-07-01 | Denali Therapeutics Inc | Compounds, compositions and methods |
| TW201920129A (zh) | 2017-09-01 | 2019-06-01 | 美商戴納立製藥公司 | 化合物、組合物及方法 |
| BR112020008825A2 (pt) | 2017-11-02 | 2020-10-20 | Calico Life Sciences Llc | moduladores da via de estresse integrada |
| UY37956A (es) | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| UY37958A (es) | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| SG11202004009TA (en) | 2017-11-02 | 2020-05-28 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
| UY37957A (es) | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| JP2021501785A (ja) | 2017-11-02 | 2021-01-21 | カリコ ライフ サイエンシーズ エルエルシー | 統合的ストレス経路の調節剤 |
| MX2020004537A (es) | 2017-11-02 | 2020-10-05 | Calico Life Sciences Llc | Moduladores de la vía integrada del estrés. |
| EP3704125B1 (en) | 2017-11-02 | 2026-03-11 | Calico Life Sciences LLC | Modulators of the integrated stress pathway |
| MX2020004538A (es) | 2017-11-02 | 2020-09-18 | Calico Life Sciences Llc | Moduladores de la vía de estrés integrada. |
| JP2021508336A (ja) | 2017-12-13 | 2021-03-04 | プラクシス バイオテック エルエルシー | 統合的ストレス応答経路の阻害剤 |
| WO2019183589A1 (en) | 2018-03-23 | 2019-09-26 | Denali Therapeutics Inc. | Modulators of eukaryotic initiation factor 2 |
| WO2019193541A1 (en) | 2018-04-06 | 2019-10-10 | Glaxosmithkline Intellectual Property Development Limited | Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors |
| WO2019193540A1 (en) | 2018-04-06 | 2019-10-10 | Glaxosmithkline Intellectual Property Development Limited | Heteroaryl derivatives of formula (i) as atf4 inhibitors |
| JP2021529814A (ja) | 2018-07-09 | 2021-11-04 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | 化学化合物 |
| WO2020031107A1 (en) | 2018-08-08 | 2020-02-13 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds |
| TW202545902A (zh) | 2018-10-11 | 2025-12-01 | 美商嘉來克生命科學有限責任公司 | 整合應激路徑之前藥調節劑 |
| CR20210426A (es) | 2019-02-13 | 2021-09-30 | Denali Therapeutics Inc | Compuestos, composiciones y métodos |
| EP3924341A4 (en) | 2019-02-13 | 2022-11-02 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| SG11202107871UA (en) | 2019-02-25 | 2021-08-30 | Praxis Biotech LLC | Inhibitors of integrated stress response pathway |
| US20220177456A1 (en) | 2019-03-06 | 2022-06-09 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| WO2020216766A1 (en) | 2019-04-23 | 2020-10-29 | Evotec International Gmbh | Modulators of the integrated stress response pathway |
| MX2021012904A (es) | 2019-04-23 | 2022-01-18 | Evotec Int Gmbh | Moduladores de la via de respuesta al estres integrada. |
| AR118836A1 (es) | 2019-04-30 | 2021-11-03 | Calico Life Sciences Llc | Moduladores de la vía de tensión integrada |
| PH12021552759A1 (en) | 2019-04-30 | 2022-07-04 | Abbvie Inc | Substituted cycloalkyls as modulators of the integrated stress pathway |
| JP2022536663A (ja) | 2019-06-12 | 2022-08-18 | プラクシス バイオテック エルエルシー | 統合的ストレス応答経路のモジュレーター |
| JP2022536901A (ja) | 2019-06-12 | 2022-08-22 | プラクシス バイオテック エルエルシー | 統合的ストレス応答経路の阻害剤 |
-
2019
- 2019-06-05 US US16/432,445 patent/US11166942B2/en not_active Expired - Fee Related
- 2019-06-05 SG SG11202011014VA patent/SG11202011014VA/en unknown
- 2019-06-05 CA CA3100715A patent/CA3100715A1/en active Pending
- 2019-06-05 AU AU2019282253A patent/AU2019282253A1/en not_active Abandoned
- 2019-06-05 MX MX2020013269A patent/MX2020013269A/es unknown
- 2019-06-05 EP EP19815149.0A patent/EP3801522A4/en not_active Withdrawn
- 2019-06-05 JP JP2020567794A patent/JP2021527044A/ja active Pending
- 2019-06-05 WO PCT/US2019/035593 patent/WO2019236710A1/en not_active Ceased
- 2019-06-05 KR KR1020217000081A patent/KR20210021519A/ko not_active Withdrawn
- 2019-06-05 BR BR112020023115-0A patent/BR112020023115A2/pt not_active Application Discontinuation
- 2019-06-05 CN CN201980050294.XA patent/CN112912082A/zh active Pending
-
2020
- 2020-11-26 CL CL2020003074A patent/CL2020003074A1/es unknown
- 2020-12-02 IL IL279151A patent/IL279151A/en unknown
-
2021
- 2021-08-10 US US17/398,902 patent/US20220071966A1/en not_active Abandoned
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991001979A1 (fr) * | 1989-08-02 | 1991-02-21 | Fujisawa Pharmaceutical Co., Ltd. | Nouveaux derives d'aminopiperazine |
| JP2001511766A (ja) * | 1997-02-17 | 2001-08-14 | 藤沢薬品工業株式会社 | 新規アミノピペラジン誘導体 |
| JP2010533685A (ja) * | 2007-07-16 | 2010-10-28 | サノフイ−アベンテイス | ピラゾール3,5カルボキシレート誘導体、これらの調製および治療上の適用 |
| JP2016517442A (ja) * | 2013-03-15 | 2016-06-16 | ウォルター,ピーター | eIF2α経路の調節因子 |
| WO2017212425A1 (en) * | 2016-06-08 | 2017-12-14 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds as atf4 pathway inhibitors |
| WO2017212423A1 (en) * | 2016-06-08 | 2017-12-14 | Glaxosmithkline Intellectual Property Development Limited | Chemcical compounds |
Non-Patent Citations (1)
| Title |
|---|
| DENIS M. BAILEY ET AL.: "Lowering of serum lipid levels by "Masked" nicotinic acid derivatives", JOURNAL OF MEDICINAL CHEMISTRY, vol. 15, no. 4, JPN6023020712, April 1972 (1972-04-01), pages 344 - 348, ISSN: 0005221518 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3801522A1 (en) | 2021-04-14 |
| MX2020013269A (es) | 2021-02-18 |
| AU2019282253A1 (en) | 2020-11-26 |
| BR112020023115A2 (pt) | 2021-02-02 |
| US20200101047A1 (en) | 2020-04-02 |
| SG11202011014VA (en) | 2020-12-30 |
| KR20210021519A (ko) | 2021-02-26 |
| EP3801522A4 (en) | 2022-06-01 |
| CA3100715A1 (en) | 2019-12-12 |
| IL279151A (en) | 2021-01-31 |
| US11166942B2 (en) | 2021-11-09 |
| US20220071966A1 (en) | 2022-03-10 |
| WO2019236710A1 (en) | 2019-12-12 |
| CL2020003074A1 (es) | 2021-04-16 |
| CN112912082A (zh) | 2021-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11230542B2 (en) | Inhibitors of integrated stress response pathway | |
| US11166942B2 (en) | Inhibitors of integrated stress response pathway | |
| JP2022521605A (ja) | 統合的ストレス応答経路の阻害剤 | |
| US11318133B2 (en) | Modulators of integrated stress response pathway | |
| US20210317102A1 (en) | Inhibitors of integrated stress response pathway | |
| US20230083885A1 (en) | Modulators of integrated stress response pathway | |
| US20170174661A1 (en) | Salt forms and polymorphs of (r)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamido) pyridazin-3-yl)-2-fluorobutyl)-n-methyl-1h-1,2,3-triazole-4-carboxamide | |
| US20200170966A1 (en) | Use of aminomethylenecyclohexane-1,3-dione compound | |
| JP6562939B2 (ja) | 三環系プロドラッグ | |
| US20230042881A1 (en) | Modulators of integrated stress response pathway | |
| HK40074323A (en) | Modulators of integrated stress response pathway |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20220202 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20220202 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220603 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220603 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230523 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230525 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20231219 |